v3.24.2.u1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Operating expenses:    
Research and development $ 75,473 $ 50,575
Acquired in-process research and development 0 12,500
General and administrative 18,808 15,402
Total operating expenses 94,281 78,477
Interest income (7,180) (4,065)
Other income, net (28) (464)
Loss before provision (benefit) for income taxes (87,073) (73,948)
Provision (benefit) for income taxes 77 (11)
Net loss $ (87,150) $ (73,937)
Net loss per common share - basic (in dollars per share) $ (0.60) $ (0.57)
Net loss per common share - diluted (in dollars per share) $ (0.60) $ (0.57)
Weighted-average common shares outstanding – basic (in shares) 146,085,729 130,503,264
Weighted-average common shares outstanding – diluted (in shares) 146,085,729 130,503,264

Source